This article is more than 5 years old. Information may no longer be current.
Abbott to acquire OptiMedica for up to $400 million
Click Here to Manage Email Alerts
Abbott has agreed to purchase OptiMedica for $250 million in cash and additional milestone payments of up to $150 million, according to a news release.
Murthy Simhambhatla, senior vice president of Abbott Medical Optics, called the move an entry point for Abbott into the femtosecond laser-assisted cataract surgery market.
“The Catalys laser system provides physicians with a state-of-the-art, computer-guided alternative in treating patients suffering from cataracts,” Simhambhatla said in the release.
The Catalys system, which has clearance from the U.S. Food and Drug Administration and a CE mark in Europe, is indicated for anterior capsulotomy, phacofragmentation, and creating single- and multi-plane arc incisions in the cornea during cataract surgery.
Abbott expects the transaction with OptiMedica to be completed by the end of the year after standard closing conditions and antitrust clearances.